Document Classification

Section Type: RESULTS

Text: After controlling for independent predictors of the composite endpoint, relative risks (RR) for the various treatments relative to naproxen 500 mg bid were : celecoxib 50 mg (RR 0. 54 ; 95 % CI 0. 37-0. 77 ; p < 0. 001), celecoxib 100 mg (RR 0. 60 ; 95 % CI 0. 45-0. 80 ; p < 0. 001), celecoxib 200 mg bid (RR 0. 63 ; 95 % CI 0. 47-0. 83 ; p = 0. 001), celecoxib 400 mg bid (RR 0. 56 ; 95 % CI 0. 35-0. 89 ; p = 0. 015), and placebo (RR 0. 63 ; 95 % CI 0. 47-0. 85 ; p = 0. 002).